FDA OKs Guardant liquid biopsy companion test to identify NSCLC

By LabPulse.com staff writers

June 2, 2021 -- The U.S. Food and Drug Administration (FDA) approved Guardant Health's liquid biopsy companion test to identify patients with nonsmall cell lung cancer (NSCLC).

The Guardant360 CDx was approved as a companion diagnostic to identify patients with NSCLC who carry the KRAS G12C mutation and may benefit from treatment with sotorasib (Lumakras) from Amgen. Lumakras is an FDA-approved KRAS G12C inhibitor.

The Guardant test's approval was based on data from clinical trial of the drug. Patients who were identified as carrying the KRAS G12C mutation via Guardant360 CDx showed an objective response rate consistent with mutations detected using traditional tissue-based biomarker diagnostics.

Natera and Guardant Health embroiled in legal battle
Cell-free DNA testing company Natera and oncology firm Guardant Health have filed dueling false-advertising legal claims over oncology diagnostic tests.
Guardant touts data presented at SABCS
Guardant Health has touted research presented at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) demonstrating how its tools benefit women...
FDA approves Guardant's liquid biopsy NGS test
The U.S. Food and Drug Administration (FDA) has approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS)...
Seoul researchers tout Guardant360 clinical results
South Korean researchers highlighted clinical results from a study that used precision oncology company Guardant Health's Guardant360 test in patients...
Liquid biopsy test detects biomarker for immunotherapy
Precision oncology company Guardant Health is touting a new study confirming that its Guardant360 liquid biopsy test can accurately detect microsatellite...

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:00:27 PM